IMMUNITYBIO, INC. (IBRX) Operating Margin
- Operating margin · 12 months: Value -151.88%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -151.88% | Operating income / revenue. Period ending 2026-06-30. $-251.80M ÷ $165.79M × 100 ≈ -151.88% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -251.80M USD | Operating Income (Loss) |
| Revenue | 165.79M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 1.09M USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-251.80M | $165.79M | $1.09M | (m) | (m) | -151.88% |
| 2026-03-31 | $-261.39M | $140.98M | $933.00K | (m) | (m) | -185.41% |
| 2025-12-31 | $-256.03M | $113.29M | $753.00K | (m) | (m) | -226.00% |
| 2025-09-30 | $-260.74M | $82.56M | $371.00K | (m) | (m) | -315.84% |
| 2025-06-30 | $-285.37M | $56.60M | $194.00K | (m) | (m) | -504.18% |
| 2025-03-31 | $-313.42M | $31.22M | $58.00K | (m) | (m) | -1003.83% |
| 2024-12-31 | $-344.18M | $14.74M | $0.00 | $190.14M | $168.78M | -2334.23% |
| 2024-09-30 | $-360.17M | $7.33M | (m) | $206.46M | $160.16M | -4912.32% |
| 2024-06-30 | $-360.05M | $1.31M | (m) | $204.41M | $156.06M | -27527.06% |
| 2024-03-31 | $-345.87M | $302.00K | (m) | $206.45M | $138.83M | -114525.17% |
| 2023-12-31 | $-362.25M | $622.00K | (m) | $232.37M | $129.62M | -58239.55% |
| 2023-09-30 | $-361.76M | $556.00K | (m) | $238.91M | $122.72M | -65064.93% |
| 2023-06-30 | $-372.43M | $592.00K | (m) | $262.12M | $110.22M | -62910.30% |
| 2023-03-31 | $-366.91M | $586.00K | (m) | $272.04M | $94.78M | -62611.95% |
| 2022-12-31 | $-351.30M | $240.00K | (m) | $248.15M | $102.71M | -146374.17% |
| 2022-09-30 | $-345.67M | $557.00K | (m) | $241.82M | $104.40M | -62059.61% |
| 2022-06-30 | $-333.70M | $505.00K | (m) | $219.49M | $114.72M | -66080.00% |
| 2022-03-31 | $-339.99M | $809.00K | (m) | $210.21M | $130.59M | -42025.71% |
| 2021-12-31 | $-330.28M | $934.00K | (m) | $195.96M | $135.26M | -35361.88% |
| 2021-09-30 | $-318.39M | $397.00K | (m) | $187.56M | $131.23M | -80199.24% |
| 2021-06-30 | $-305.43M | $482.00K | (m) | $174.06M | $121.20M | -63367.63% |
| 2021-03-31 | $-270.44M | $579.00K | (m) | $153.26M | $107.10M | -46708.46% |
| 2020-12-31 | $-91.63M | $111.00K | (m) | $64.48M | $27.25M | -82545.95% |
| 2020-09-30 | $-76.85M | $99.00K | (m) | $56.23M | $20.72M | -77627.27% |
| 2020-06-30 | $-70.99M | $43.00K | (m) | $51.00M | $20.03M | -165090.70% |
| 2020-03-31 | $-68.06M | $59.00K | (m) | $50.42M | $17.70M | -115352.54% |
| 2019-12-31 | $-67.81M | $43.00K | (m) | $49.78M | $18.07M | -157690.70% |
| 2019-09-30 | $-69.42M | $41.00K | (m) | $50.26M | $19.20M | -169304.88% |
| 2019-06-30 | $-77.46M | $60.00K | (m) | $52.77M | $24.75M | -129096.67% |
| 2019-03-31 | $-88.44M | $47.00K | (m) | $54.33M | $34.16M | -188170.21% |
| 2018-12-31 | $-98.39M | $47.00K | (m) | $55.72M | $42.72M | -209338.30% |
| 2018-09-30 | $-106.06M | $52.00K | (m) | $55.26M | $50.86M | -203969.23% |
| 2018-06-30 | $-106.40M | $29.00K | (m) | $51.77M | $54.66M | -366889.66% |
| 2018-03-31 | $-101.94M | $39.00K | (m) | $46.79M | $55.19M | -261384.62% |
| 2017-12-31 | $-99.12M | $45.00K | (m) | $42.04M | $57.12M | -220266.67% |
| 2017-09-30 | $-98.87M | $47.00K | (m) | $39.47M | $59.45M | -210361.70% |
| 2017-06-30 | $-107.20M | $51.00K | (m) | $36.76M | $70.49M | -210201.96% |
| 2017-03-31 | $-118.35M | $49.00K | (m) | $33.45M | $84.95M | -241526.53% |
| 2016-12-31 | $-124.50M | $44.00K | (m) | $29.15M | $95.39M | -282954.55% |
| 2016-09-30 | (m) | $44.00K | (m) | $23.78M | $105.55M | (m) |
| 2016-06-30 | (m) | $43.00K | (m) | $20.10M | $122.90M | (m) |
| 2016-03-31 | (m) | $122.00K | (m) | $15.78M | $222.71M | (m) |
| 2015-12-31 | (m) | $236.00K | (m) | $11.43M | $227.68M | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $475.00K | (m) | (m) | $35.25M | (m) |
| 2014-12-31 | $-5.58M | $641.00K | (m) | $1.59M | $4.62M | -869.73% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $600.00K | (m) | $446.00K | $2.42M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |